The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in san francisco

Clinical Infectious Diseases

Volumn 52, Issue 8, 2011, Pages 1046-1049

  Charlebois, Edwin D ^a,b   Das, Moupali ^a,c   Porco, Travis C ^c   Havlir, Diane V ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; EPIDEMIC; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG UTILIZATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MODELS, STATISTICAL; SAN FRANCISCO;

EID: 79953846656     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir085     Document Type: Article

References (21)

1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
2. Zetola NM, Bernstein K, Ahrens K, et al. Using surveillance data to monitor entry into care of newly diagnosed HIV-infected persons: San Francisco, 2006-2007. BMC Public Health 2009; 9:17.
3. HIV/AIDS Statistics and Epidemiology Section. HIV/AIDS Epidemiology Annual Report 2008. San Francisco: San Francisco Department of Public Health, 2009.
4. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4. (Pubitemid 30070912)
5. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-35.
6. HIV/AIDS Statistics and Epidemiology Section. HIV/AIDS Epidemiology Annual Report 2008. San Francisco: San Francisco Department of Public Health, 2009.
7. Schechter MT, Le N, Craib KJ, Le TN, O'Shaughnessy MV, Montaner JS. Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:474-9.
8. Grant RM, Wiley JA, Winkelstein W. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis 1987; 156:189-93. (Pubitemid 17089402)
9. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-8.
10. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-forgotten but not gone. N Engl J Med 2010; 362:967-70.
11. Scheer S, Chin CS, Buckman A, McFarland W. Estimation of HIV incidence in San Francisco. AIDS 2009; 23:533-4.
12. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008; 372:669-84.
13. Department of Health & Human Services (DHHS). Panel on anti-retroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at:l http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed 2010 1-161.
14. Walensky RP, Paltiel AD, Losina E, et al. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
15. Charlebois ED, Havlir DV. "A bird in the hand": a commentary on the test and treat approach for HIV. Arch Intern Med 2010; 170:1354-6.
16. Okie S. Fighting H.I.V., a community at a time. New York Times, 2009. October 26 2009.
17. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis 2002; 15:609-14. (Pubitemid 36026974)
18. Jain V, Pilcher C, Deeks S, et al. Increasing prevalence of NNRTI-associated drug-resistance mutations in patients with acute, early HIV in San Francisco. 16th Conference on Retroviruses and Opportunistic infections. Boston: Massachusetts, 2009.
19. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
20. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
21. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-9.